NASDAQ:PLXP PLx Pharma (PLXP) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PLXP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,000 shsAverage Volume12.96 million shsMarket Capitalization$603,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About PLx Pharma Stock (NASDAQ:PLXP)PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.Read More Ad InvestorPlaceHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs PLXP Stock News HeadlinesJanuary 30, 2024 | investing.comProtalix Biotherapeutics Inc (PLX)January 22, 2024 | morningstar.comVertex Pharmaceuticals Inc VRTXOctober 23, 2023 | investing.comVietnam National Petroleum Group (PLX)August 21, 2023 | uk.investing.comPLx Pharma Inc (PLXPQ)April 21, 2023 | seekingalpha.comPLXPQ PLx Pharma Inc.April 13, 2023 | marketwatch.comPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its AssetsApril 12, 2023 | msn.comWhy PLx Pharma Shares Are Nosediving TodayApril 12, 2023 | msn.comWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketApril 11, 2023 | msn.comWhy PLx Pharma Shares Are Down Over 40% TuesdayApril 11, 2023 | finance.yahoo.comPLx Pharma Inc. Receives Nasdaq Delisting NoticeApril 11, 2023 | msn.comShort Volatility Alert: Plx Pharma IncDecember 22, 2022 | msn.comPLx Pharma's Return On Capital Employed InsightsNovember 11, 2022 | seekingalpha.comPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | seekingalpha.comPLx Pharma down after Q3 revenue fell 94% Y/YNovember 10, 2022 | finance.yahoo.comPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | msn.comEarnings Preview: PLx PharmaOctober 26, 2022 | finance.yahoo.comPLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business UpdateSeptember 12, 2022 | finance.yahoo.comBaseball Legend John Smoltz Featured on PLx Pharma’s Social ChannelsSeptember 5, 2022 | finance.yahoo.comPLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52kAugust 20, 2022 | finance.yahoo.comPLXP Aug 2022 5.000 callAugust 15, 2022 | seekingalpha.comPLx Pharma downgraded at Oppenheimer after Q2 missAugust 12, 2022 | marketwatch.comPLx Pharma to Explore Strategic Alternatives, Reduces TeamAugust 12, 2022 | apnews.comSurvey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mgAugust 12, 2022 | markets.businessinsider.comPLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%See More Headlines Company Calendar Last Earnings11/12/2021Today5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PLXP CUSIPN/A CIK1497504 Webwww.plxpharma.com Phone(973) 409-6541Fax713-842-3052Employees16Year Founded2002Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,130,000.00 Net Margins-606.91% Pretax Margin-606.91% Return on Equity-291.11% Return on Assets-119.43% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.28 Sales & Book Value Annual Sales$4.54 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / BookN/AMiscellaneous Outstanding Shares29,138,000Free Float26,530,000Market Cap$603,000.00 OptionableNot Optionable Beta3.79 Social Links Key ExecutivesNatasha GiordanoPresident, Chief Executive Officer & DirectorRita M. O'ConnorCFO, Head-Manufacturing & Supply ChainMayme Lou RoettigExecutive Medical DirectorThomas L. LongVP-Manufacturing & Technical OperationsLawrence R. PerkinsChief Restructuring OfficerKey CompetitorsComera Life SciencesNASDAQ:CMRAAditxtNASDAQ:ADTXBellerophon TherapeuticsNASDAQ:BLPHChina SXT PharmaceuticalsNASDAQ:SXTCAptevo TherapeuticsNASDAQ:APVOView All Competitors PLXP Stock Analysis - Frequently Asked Questions How were PLx Pharma's earnings last quarter? PLx Pharma Inc. (NASDAQ:PLXP) released its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to analysts' expectations of $4.10 million. PLx Pharma had a negative trailing twelve-month return on equity of 291.11% and a negative net margin of 606.91%. PLx Pharma's revenue for the quarter was up 560.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.40) EPS. What other stocks do shareholders of PLx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX). When did PLx Pharma IPO? PLx Pharma (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers. This page (NASDAQ:PLXP) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist My Default Watchlist Adding PLx Pharma Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.